Trial Profile

Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Safety Study in Adult and Pediatric Subjects.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peanut allergy immunotherapy (Primary)
Indications Peanut hypersensitivity
Focus Adverse reactions; First in man
Acronyms PEP01.09
Sponsors DBV Technologies

Most Recent Events

25 Feb 2016 Results published in DBV Technologies media release.
25 Feb 2016 According to DBV Technologies media release, results of this trial is published in the Journal of Allergy and Clinical Immunology (JACI).
18 Jun 2012 Full results were reported at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI), and in a DBV Technologies media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com